Rising Stroke Rates in Californians With SCD

TOPLINE:
Stroke rates in Californians with sickle cell disease (SCD) have increased in both children and adults in the post-STOP era. The cumulative incidence of first ischemic stroke was 2.1% by age 20 and 13.5% by age 60.
METHODOLOGY:
Researchers analyzed data from the California Department of Health Care Access and Innovation (HCAI), covering emergency department and hospitalization records from 1991 to 2019.
A total of 7636 patients with SCD were included in the study cohort.
Cumulative incidence and rates for primary and recurrent strokes and transient ischemic attacks (TIAs) were determined pre- and post-STOP trial.
Patients with SCD were identified using ICD-9 and ICD-10 codes, with specific criteria for inclusion based on hospitalization records.
The study utilized Fine and Gray methodology to calculate cumulative incidence functions, accounting for the competing risk for death.
TAKEAWAY:
The cumulative incidence of first ischemic stroke in patients with SCD was 2.1% by age 20 and 13.5% by age 60.
Ischemic stroke rates increased significantly in children and adults in the 2010-2019 period compared with the preceding decade.
Risk factors for stroke and TIA included increasing age, hypertension, and hyperlipidemia.
The study found a significant increase in rates of intracranial hemorrhage in adults aged 18-30 years and TIAs in children younger than 18 years from 2010 to 2019 compared with the prior decade.
IN PRACTICE:
“Neurovascular complications, including strokes and transient ischemic attacks (TIAs), are common and cause significant morbidity in individuals with sickle cell disease (SCD). The STOP trial (1998) established chronic transfusions as the standard of care for children with SCD at high risk for stroke,” the study’s authors wrote.
SOURCE:
This study was led by Olubusola B. Oluwole, MD, MS, University of Pittsburgh in Pittsburgh, and was published online in Blood.
LIMITATIONS:
This study’s reliance on administrative data may have introduced systematic errors, particularly with the transition from ICD-9 to ICD-10 codes. The lack of laboratory results and medication data in the HCAI database limited the ability to fully assess patient conditions and treatments. Additionally, the methodology changes in 2014 likely underreported death rates in people without PDD/EDU encounters in the calendar year preceding their death.
DISCLOSURES:
The authors reported no relevant conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
 
Send comments and news tips to [email protected].